MedTrace Logo

An Expanded Access Protocol to Provide Avexitide in Patients With Post-Bariatric Hypoglycemia

NCT07582874 · Status: AVAILABLE · Type: EXPANDED_ACCESS

Last updated 2026-05-13

No results posted yet for this study

Summary

The Expanded Access Program will provide access to avexitide for people with post-bariatric hypoglycemia (PBH) following Roux-en-Y gastric bypass (RYGB) who meet the eligibility criteria for this program. The safety of avexitide and patient treatment experience will be monitored during this program.

Conditions

  • Post-bariatric Hypoglycemia

Interventions

DRUG

Avexitide

90 mg subcutaneous injection once per day at least one hour prior to first meal of the day.

Sponsors & Collaborators

  • Amylyx Pharmaceuticals Inc.

    lead INDUSTRY

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07582874 on ClinicalTrials.gov